Raser Jeffrey 4

4 · Somaxon Pharmaceuticals, Inc. · Filed Mar 3, 2010

Form 4

Period: 2010-03-01

Senior VP, Sales and Marketing

Transactions

Exercise/Conversion
Common Stock
2010-03-01−19,444→ 13,889 total
Exercise: $1.23Exp: 2017-03-01→ Common Stock (19,444 underlying)
Exercise/Conversion
Common Stock
2010-03-01−5,446→ 77,887 total
Exercise: $1.23Exp: 2019-02-16→ Common Stock (5,446 underlying)
Exercise/Conversion
Common Stock
2010-03-01$1.23/sh+19,444$23,916→ 43,554 total
Exercise/Conversion
Common Stock
2010-03-01−24,110→ 17,223 total
Exercise: $1.23Exp: 2016-01-05→ Common Stock (24,110 underlying)
Exercise/Conversion
Common Stock
2010-03-01$1.23/sh+24,110$29,655→ 24,110 total
Exercise/Conversion
Common Stock
2010-03-01$1.23/sh+35,000$43,050→ 78,554 total
Exercise/Conversion
Common Stock
2010-03-01$1.23/sh+5,446$6,699→ 84,000 total
Sale
Common Stock
2010-03-01$4.08/sh−84,000$342,367→ 0 total
Exercise/Conversion
Common Stock
2010-03-01−35,000→ 25,000 total
Exercise: $1.23Exp: 2018-02-18→ Common Stock (35,000 underlying)

Footnotes (3)

[F1]This sale was effected by the reporting person pursuant to a pre-planned selling program under Rule 10b5-1 adopted by the reporting person in 2009.
[F2]1/3 of the shares of Common Stock subject to this grant vested on the date of grant (June 9, 2009) and the remaining shares will vest and become exercisable in 24 equal monthly installments over the following two year period.
[F3]Not applicable.

Documents

1 file